EXTON, Pa., July 6 /PRNewswire-FirstCall/ -- Isolagen, Inc. today announced that the Company’s Chief Financial Officer (CFO), Declan Daly, has been appointed to the position of Chief Operating Officer. In addition to his current responsibilities as CFO, Mr. Daly will oversee Manufacturing Operations, Clinical & Regulatory Affairs and Quality Systems. He will continue to report to Nicholas L. Teti, Jr., Isolagen Chairman and Chief Executive Officer and serve as a member of the executive leadership team.
“I am extremely pleased to promote Declan to Chief Operating Officer. I have worked with him for many years and know that he has the skills, experience and commitment needed to drive the growth and success of Isolagen,” said Mr. Teti. “Continuing to streamline management responsibilities will help enhance our focus on achieving key Company objectives.”
Mr. Daly, 44, has served as Isolagen’s Chief Financial Officer and Executive Vice President, Europe since June 2006. Prior to joining Isolagen, he served as Executive Vice President and Chief Financial Officer at Inamed Corp. Mr. Daly holds a B.A. in Management Science and Industrial Systems Studies from Trinity College, Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.
About Isolagen, Inc.
Isolagen(TM), Inc. is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company’s technology platform includes the Isolagen Process(TM), a novel cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of applications including facial rejuvenation and wrinkles, acne scars, burn scars and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com .
Forward Looking Statements
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2006, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.
Isolagen, Inc.
CONTACT: Media, Mike Beyer of Sam Brown Inc. for Isolagen, Inc.,+1-773-463-4211, beyer@sambrown.com; or Investors, Charles Huiner ofIsolagen, Inc., +1-484-713-6200, chuiner@isolagen.com
Web site: http://www.isolagen.com/
